Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT + KarX-EC in Children and Adolescents With Irritability Associated With Autism Spectrum Disorder
NCT07284745Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2026
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing KarXT + KarX-EC Arm with Placebo Arm (2 arms). Primary endpoint: Aberrant Behavior Checklist Irritability Score at 8 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
xanomelineKarX-EC
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07284745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284745.